Published April 27, 2026
Latest Drug Approvals from Health Canada
Weekly roundup of notable drug approvals relevant to Canada's pharmacies.
Read more about Latest Drug Approvals from Health CanadaPublished April 21, 2026
Drug Pipeline Insights: Generic Pharmaceuticals
Our 2026 Q1 Generics Insights highlights a wave of high-value generic launches—including major diabetes and oncology drugs—signaling one of the most commercially impactful years for pharmacy in over …
Read more about Drug Pipeline Insights: Generic PharmaceuticalsPublished April 21, 2026
Drug Pipeline Spotlight: Semaglutide
Our Drug Pipeline Spotlight on Semaglutide explores the explosive growth of GLP-1 therapies like Ozempic, Wegovy, and Rybelsus, the anticipated entry of generics in 2026, and what it all means for ph…
Read more about Drug Pipeline Spotlight: SemaglutidePublished April 21, 2026
Drug Pipeline Insights: Biosimilars
Our 2026 Q1 Biosimilars Insights shows an increasingly crowded biosimilars market—led by blockbuster biologics like aflibercept and denosumab—creates new competitive dynamics and savings opportunitie…
Read more about Drug Pipeline Insights: BiosimilarsPublished April 21, 2026
Drug Pipeline Insights: New Drugs
Our 2026 Q1 New Drugs Insights demonstrates how the the latest round of new drug approvals and submissions, from rare disease breakthroughs to cutting-edge oncology therapies, is set to res…
Read more about Drug Pipeline Insights: New DrugsPublished April 9, 2026
From the Desk of the CEO - 2026 Q1 Update
Neighbourhood Pharmacies releases its Q1 2026 From the Desk of the CEO letter.
Read more about From the Desk of the CEO - 2026 Q1 Update